Proteomics

Dataset Information

0

Hexosamine Pathway Disruption by GFPT1 Loss Drives Coordinated Defects in Glycosylation, Autophagy, and Trafficking


ABSTRACT: Gfpt1, the rate limiting enzyme of the hexosamine biosynthetic pathway (HBP), provides the UDP-GlcNAc required for protein glycosylation. Biallelic mutations in GFPT1 cause congenital myasthenic syndromes (GFPT1-CMS), yet the molecular mechanisms linking impaired glycosylation to skeletal muscle dysfunction remain incompletely understood. Here, we combine cellular models of inducible Gfpt1 knockdown and a muscle-specific Gfpt1 knockout mouse (Gfpt1Tm1d/Tm1d) with whole-cell proteomics, immunoblot studies and secretomics to define glycosylation-dependent defects in intracellular trafficking, ER stress signaling and autophagy. Global proteomic profiling of Gfpt1-deficient myoblasts revealed marked downregulation of protein trafficking pathways and impaired secretion of key muscle cargo proteins, including Srgn. Loss of GFPT1 reduced both high–molecular weight glycosylated SRGN and its core protein, accompanied by intracellular retention and decreased secretion. These trafficking defects coincided with robust activation of the unfolded protein response (UPR), evidenced by increased Xbp1 expression and accumulation of spliced Xbp1s across pharmacologic, cellular, and mouse models of GFPT1 deficiency. Converging evidence from proteomics, immunoblotting, and immunofluorescence demonstrated impaired autophagy, including increased LC3 II accumulation, elevated p62/SQSTM1 levels, and enhanced p62 positive puncta in both myoblasts and Gfpt1-deficient skeletal muscle. Soluble/insoluble fractionation further confirmed p62 accumulation, indicating defective autophagic flux and buildup of aggregated cargo. Together, these findings identify a glycosylation dependent failure in protein trafficking that triggers ER stress, UPR activation, and autophagy impairment in Gfpt1-deficient skeletal muscle. This mechanistic cascade provides a unifying explanation for muscle pathology in GFPT1 associated congenital myasthenic syndromes and suggests that restoring glycosylation or improving proteostasis may represent viable therapeutic approaches.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Culture

SUBMITTER: Andreas Hentschel  

LAB HEAD: Prof. Dr. Albert Sickmann

PROVIDER: PXD079191 | Pride | 2026-08-04

REPOSITORIES: Pride

Similar Datasets

2014-09-30 | E-GEOD-34896 | biostudies-arrayexpress
2018-05-04 | PXD008145 | Pride
2014-05-22 | E-GEOD-38643 | biostudies-arrayexpress
2014-09-30 | GSE34896 | GEO
2009-03-12 | GSE15182 | GEO
2010-10-14 | E-GEOD-20415 | biostudies-arrayexpress
2014-10-10 | E-GEOD-62210 | biostudies-arrayexpress
2021-07-07 | PXD023872 | Pride
2024-10-22 | GSE254276 | GEO
2024-10-22 | GSE254277 | GEO